Immediate Impact
15 standout
Citing Papers
The anti-PD-L1/CTLA-4 bispecific antibody KN046 plus lenvatinib in advanced unresectable or metastatic hepatocellular carcinoma: a phase II trial
2025 Standout
Clinical spectrum and evolution of immune-checkpoint inhibitors toxicities over a decade—a worldwide perspective
2024 Standout
Works of Chenyang Zhan being referenced
Safety of Combined Yttrium-90 Radioembolization and Immune Checkpoint Inhibitor Immunotherapy for Hepatocellular Carcinoma
2019
Author Peers
| Author | Last Decade | Papers | Cites | ||||
|---|---|---|---|---|---|---|---|
| Chenyang Zhan | 52 | 118 | 65 | 172 | 14 | 340 | |
| E Lubat | 130 | 50 | 115 | 168 | 15 | 404 | |
| Paolo Cabassa | 53 | 203 | 140 | 59 | 21 | 397 | |
| Mauro Mattace Raso | 146 | 72 | 43 | 101 | 21 | 356 | |
| Christian Goerg | 237 | 49 | 48 | 142 | 24 | 402 | |
| Alfred Heilbrunn | 95 | 81 | 145 | 140 | 18 | 368 | |
| Marcus J. Dill-Macky | 59 | 158 | 91 | 75 | 13 | 323 | |
| Khlar E. McDonald | 149 | 130 | 154 | 91 | 13 | 377 | |
| Sam Grigg | 114 | 45 | 51 | 43 | 11 | 359 | |
| Jieun Park | 110 | 181 | 82 | 115 | 12 | 317 | |
| Pietro Brambillasca | 92 | 97 | 48 | 116 | 14 | 317 |
All Works
Login with ORCID to disown or claim papers
Loading papers...